1. Home
  2. RGEN vs CORT Comparison

RGEN vs CORT Comparison

Compare RGEN & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Repligen Corporation

RGEN

Repligen Corporation

HOLD

Current Price

$162.25

Market Cap

8.2B

Sector

Health Care

ML Signal

HOLD

Logo Corcept Therapeutics Incorporated

CORT

Corcept Therapeutics Incorporated

HOLD

Current Price

$84.58

Market Cap

8.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RGEN
CORT
Founded
1981
1998
Country
United States
United States
Employees
N/A
500
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.2B
8.6B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RGEN
CORT
Price
$162.25
$84.58
Analyst Decision
Buy
Buy
Analyst Count
10
6
Target Price
$174.90
$130.20
AVG Volume (30 Days)
681.2K
890.8K
Earning Date
10-28-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.03
0.87
Revenue
$707,890,000.00
$741,172,000.00
Revenue This Year
$17.84
$23.79
Revenue Next Year
$12.57
$40.97
P/E Ratio
$6,198.22
$93.35
Revenue Growth
11.74
17.92
52 Week Low
$102.97
$49.00
52 Week High
$182.52
$117.33

Technical Indicators

Market Signals
Indicator
RGEN
CORT
Relative Strength Index (RSI) 54.32 53.95
Support Level $156.01 $78.07
Resistance Level $165.02 $89.00
Average True Range (ATR) 4.65 3.58
MACD -1.06 -0.37
Stochastic Oscillator 44.27 46.98

Price Performance

Historical Comparison
RGEN
CORT

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

About CORT Corcept Therapeutics Incorporated

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.

Share on Social Networks: